Faculty ProfilesEdward Hsiao, MD, PhD
MD: MD, PhD, Johns Hopkins Medical School, 2001
Residency: Johns Hopkins Hospital, Baltimore, MD, Internal Medicine, 2001-2004
Fellowship: UCSF, Division of Diabetes, Endocrinology and Metabolism, 2004-2007
Board Certifications: Internal Medicine, 2004; Endocrinology and Metabolism, 2006
My research is driven by a desire to understand how major hormonal and regulatory pathways determine the specification, differentiation, and morphogenesis of mesenchymal tissues such as bone, cartilage, muscle, and fat. Mis-regulation of these pathways leads to significant medical diseases, including the inappropriate formation of mineralized tissues in atherosclerosis, heterotopic ossification, and cancer.
My research focuses on understanding how these regulatory signals control normal and pathologic tissue formation as a way to identifying new therapeutic avenues for treating human diseases. Our laboratory takes a comprehensive approach to understanding hormone signaling in human diseases using synthetic biology approaches, mouse models, and human stem cell models.
By combining multiple approaches with state-of-the art methods, our laboratory is working to develop a broader understanding of the biology underlying skeletal development, devise novel therapeutic approaches for treating human skeletal disorders and bone injuries, and examine how hormone signals affect important tissues such as fat, muscle, bone, cartilage, and blood vessels.
General Endocrinology with an interest in inherited skeletal diseases, including fibrous dysplasia of the bone (FD), McCune-Albright syndrome (MAS), and fibrodysplasia ossificans progressiva (FOP).
Availability: General Endocrinology, 3rd Tuesday PM of each month
Laboratory website: http://tiny.ucsf.edu/hsiaolab
Recent Articles (10)
Mantick N, Bachman E, Baujat G, Brown M, Collins O, De Cunto C, Delai P, Eekhoff M, Zum Felde R, Grogan DR, Haga N, Hsiao E, Kantanie S, Kaplan F, Keen R, Milosevic J, Morhart R, Pignolo R, Qian X, di Rocco M, Scott C, Sherman A, Wallace M, Williams N, Zhang K, Bogard B. The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva. Bone. 2017 Aug 30.
Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, Whitehead B, Jacobs B, Siegel DM, Keen R, Hsiao E, Pignolo RJ. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. Bone. 2017 Jul 20.
Di Rocco M, Baujat G, Bertamino M, Brown M, De Cunto CL, Delai PLR, Eekhoff EMW, Haga N, Hsiao E, Keen R, Morhart R, Pignolo RJ, Kaplan FS. International physician survey on management of FOP: a modified Delphi study. Orphanet J Rare Dis. 2017 Jun 12; 12(1):110.
Schmitt CE, Morales BM, Schmitz EMH, Hawkins JS, Lizama CO, Zape JP, Hsiao EC, Zovein AC. Fluorescent tagged episomals for stoichiometric induced pluripotent stem cell reprogramming. Stem Cell Res Ther. 2017 Jun 05; 8(1):132.
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics. 2017; 7(5):1149-1158.
Niethamer TK, Larson AR, O'Neill AK, Bershteyn M, Hsiao EC, Klein OD, Pomerantz JH, Bush JO. EPHRIN-B1 Mosaicism Drives Cell Segregation in Craniofrontonasal Syndrome hiPSC-Derived Neuroepithelial Cells. Stem Cell Reports. 2017 Mar 14; 8(3):529-537.